Evidence map›Paper›PMID 38561497›Full record

ArticleNature microbiology2024

Low-dose dengue virus 3 human challenge model: a phase 1 open-label study.

Adam T Waickman, Krista Newell, Joseph Q Lu, HengSheng Fang, Mitchell Waldran, Chad Gebo, Jeffrey R Currier, Heather Friberg, Richard G Jarman, Michelle D Klick and 3 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Nature microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04298138 (Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge -), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298138 phase1completednot on this map

Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge - (DENV-3-LVHC) Virus Strain

TypeinterventionalSponsorState University of New York - Upstate Medical UniversityRan2020 to 2021Enrolled9ConditionsDengueArmsDengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Dengue and severe dengue.Clinical microbiology reviews · 2025
    Review
  8. Dengue Virus NS1 Binds Ephrin B1 to Trigger Endothelial Dysfunction.bioRxiv : the preprint server for biology · 2025
    Article
  9. Review
  10. Proceedings of the 7Vaccines · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Adam T WaickmanDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA. waickmaa@upstate.edu.ORCID http://orcid.org/0000-0002-4536-6714
Krista NewellDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA.
Joseph Q LuDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA.ORCID http://orcid.org/0000-0002-8738-7230
HengSheng FangDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA.
Mitchell WaldranDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA.ORCID http://orcid.org/0000-0001-5614-153X
Chad GeboDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA.ORCID http://orcid.org/0000-0003-2043-4490
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Heather FribergViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Richard G JarmanViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Michelle D KlickInstitute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY, USA.
Lisa A WareInstitute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY, USA.
Timothy P EndyDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA.
Stephen J ThomasDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, USA. ThomStep@upstate.edu.ORCID http://orcid.org/0000-0002-8368-7682
SUNY Upstate Medical University · USWalter Reed Army Institute of Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of a phase 1 open-label assessment of a low-dose dengue virus 3 (DENV-3) challenge model (NCT04298138), in which nine participants received a subcutaneous inoculation with 0.5 ml of a 1.4 × 10

Indexed as

Antibodies, ViralDengueDengue VaccinesDengue VirusViremiaAdultCytokinesFemaleHumansMaleMemory T CellsMiddle AgedRNA, ViralSeroconversionYoung AdultAntibodies, ViralCytokinesDengue VaccinesRNA, Viral

Identifiers

PMID38561497
OpenAlexW4393388469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.